Aging, β-amyloid, Alzheimer's - Opinion

Area of Science:

• Neuroscience
• Gerontology
• Pharmacology

Background:

• Alzheimer's disease (AD) remains a significant therapeutic challenge despite over a century of research.
• The aging process is the primary risk factor for AD, suggesting a link between cellular aging and disease pathogenesis.
• Current treatments, including anti-amyloid antibodies, have shown limited success and are prohibitively expensive for widespread use.

Purpose of the Study:

• To propose novel research directions for Alzheimer's disease treatment.
• To explore the connection between aging, epigenetic chaos, and amyloidogenesis in AD.
• To identify cost-effective therapeutic strategies for managing AD dementia.

Main Methods:

• Literature review of aging and Alzheimer's disease research.
• Analysis of existing data on amyloidogenesis and its triggers.
• Evaluation of therapeutic potential of small molecule inhibitors versus antibody treatments.

Main Results:

• Aging is identified as the strongest risk factor for AD.
• Amyloidogenesis is proposed to result from molecular events leading to epigenetic chaos.
• Small molecule inhibitors are presented as a more economically viable alternative to antibodies for AD treatment.

Conclusions:

• A new therapeutic approach for AD is needed, focusing on underlying aging processes.
• Targeting amyloidogenesis with small molecules holds promise for halting AD dementia.
• Cost-effectiveness is a critical factor in developing scalable AD treatments.